enobosarm Report issue

Small molecule Experimental
AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW
  • Now
Enobosarm, also known as ostarine or MK-2866, is an investigational selective androgen receptor modulator (SARM) developed by GTx, Inc. for the treatment of conditions such as muscle wasting and osteoporosis, formerly under development by Merck & Company.   Wikipedia

Chemistry

  • SMILES: C[C@](O)(COc1ccc(cc1)C#N)C(=O)Nc2ccc(C#N)c(c2)C(F)(F)F
  • InChIKey: JNGVJMBLXIUVRD-SFHVURJKSA-N
  • Mol. Mass: 389.33
  • ALogP: 3.22
  • ChEMBL Molecule:
    enobosarm  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Missing data
  • Delivery Methods: Missing data
  • Pro Drug: No

Alternative names

enobosarm | gtx 024 | gtx-024 | mk2866 | mk 2866 | mk-2866 | ostarine

Organizations (10)

Research & Development (10)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (0)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (8)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Androgens (Phase 2)

Breast Density (Phase 1)

Breast Neoplasms (Phase 3)

Cachexia (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 3)

Triple Negative Breast Neoplasms (Phase 2)

Urinary Incontinence, Stress (Phase 2)

Wasting Disease, Chronic (Phase 3)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 15
  • # of Trial Organizations: 10

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue